Phase Ib Study of Erlotinib Prior to Surgery in Patients With Head and Neck Cancer
Phase 1 Completed
48 enrolled
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin Followed By Chemoradiation in Treating Patients With Recurrent Head and Neck Cancer
Phase 1 Completed
48 enrolled
Adjuvant Erlotinib After Completing Chemoradiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Phase 1 Completed
19 enrolled
DUET-2
Phase 1 Completed
150 enrolled
Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer
Phase 1 Completed
15 enrolled
RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma
Phase 1 Completed
53 enrolled
Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Phase 1 Completed
3 enrolled
Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer
Phase 1 Completed
31 enrolled
Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors
Phase 1 Completed
33 enrolled
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
Phase 1 Completed
43 enrolled
Immunotoxin Therapy in Treating Patients With Advanced Cancer
Phase 1 Completed
Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors
Phase 1 Completed
Vaccine Therapy in Treating Patients With Advanced or Recurrent Cancer
Phase 1 Completed
TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck
Phase 1 Completed
13 enrolled
Vaccine Therapy in Treating Patients With Advanced or Metastatic Cancer
Phase 1 Completed
14 enrolled
7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
Phase 1 Completed
41 enrolled
Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors
Phase 1 Completed
35 enrolled
Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer
Phase 1 Completed
Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer
Phase 1 Completed
Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors
Phase 1 Completed
30 enrolled
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
Phase 1 Completed
15 enrolled
Biological Therapy in Treating Patients With Metastatic Cancer
Phase 1 Completed
24 enrolled
Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer
Phase 1 Completed
24 enrolled
Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer
Phase 1 Completed
39 enrolled
Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer
Phase 1 Completed
48 enrolled
Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
Phase 1 Completed
75 enrolled
NGR-TNF in Treating Patients With Advanced Solid Tumors
Phase 1 Completed
70 enrolled
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
Phase 1 Completed
75 enrolled
Boronophenylalanine-Fructose Complex (BPA-F) and/or Sodium Borocaptate (BSH) Followed By Surgery in Treating Patients With Thyroid Cancer, Head and Neck Cancer, or Liver Metastases
Phase 1 Completed
27 enrolled
Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors
Phase 1 Completed
Thalidomide and Docetaxel in Treating Patients With Advanced Cancer
Phase 1 Completed
26 enrolled
SU5416 and Paclitaxel in Treating Patients With Recurrent, Locally Advanced or Metastatic Cancer of the Head and Neck
Phase 1 Completed
12 enrolled